Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.55 |
| ▸ | DNMT3L | Q9UJW3 | 2/20 | 0.55 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.55 |
| ▸ | AMD1 | P17707 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12218294 | 0.89 | RAB9A (0.65) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL13288395 | 0.81 | POLA1 (0.63) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL13963083 | 0.81 | RAB9A (0.71) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL12218261 | 0.80 | RAB9A (0.76) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL12218264 | 0.80 | RAB9A (0.76) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL1887031 | 0.79 | DNMT1 (0.60) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL4523617 | 0.79 | RAB9A (0.73) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL13963078 | 0.78 | RAB9A (0.71) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL13963079 | 0.78 | RAB9A (0.71) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 | |
| SCHEMBL3500070 | 0.77 | CYP1A2 (1.00) | RAB9ACYP1A2NPC1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2174938-A1 | Quinoline derivatives for modulating DNA methylation | SuperGen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | RAB9A 2538/4885CYP1A2 695/4885NPC1 3069/4885 |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | RAB9A 2538/4885CYP1A2 695/4885NPC1 3069/4885 |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | RAB9A 2538/4885CYP1A2 695/4885NPC1 3069/4885 |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | RAB9A 2538/4885CYP1A2 695/4885NPC1 3069/4885 |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | RAB9A 2538/4885CYP1A2 695/4885NPC1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.